Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug
Roche dived into the MASH space by agreeing to hand over up to $3.5 billion for 89bio and its phase-3-stage candidate.
James Waldron
Sep 18, 2025 5:02am
Sponsored
Identifying Undervalued Assets to Address Unmet Patient Needs
Sep 15, 2025 8:00am
Pfizer, Arvinas lose interest in commercializing PROTAC drug
Sep 18, 2025 7:35am
ArsenalBio halves staff amid reorganization efforts
Sep 17, 2025 4:55pm
Massachusetts most impacted by NIH research cuts: Grant Witness
Sep 18, 2025 9:38am
QL Biopharm links monthly GLP-1 to incumbent-rivaling efficacy
Sep 18, 2025 7:20am
More News
Stryker, Siemens Healthineers team up for stroke-treating robot
Sep 18, 2025 11:30am
Carisma’s lifeline disappears as reverse merger plans break down
Sep 18, 2025 10:40am
Biogen inks $85M Alcyone buyout to acquire drug delivery tech
Sep 18, 2025 10:30am
Fierce Biotech Layoff Tracker 2025: Arvinas, Novo, BMS & more
Sep 18, 2025 10:20am
See more stories